1,479 reports of this reaction
2.4% of all NALTREXONE reports
#9 most reported adverse reaction
HEADACHE is the #9 most commonly reported adverse reaction for NALTREXONE, manufactured by Alkermes, Inc.. There are 1,479 FDA adverse event reports linking NALTREXONE to HEADACHE. This represents approximately 2.4% of all 60,963 adverse event reports for this drug.
NALTREXONE has an overall safety score of 78 out of 100. Patients taking NALTREXONE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for NALTREXONE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for NALTREXONE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,479 FDA reports for NALTREXONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.4% of all adverse event reports for NALTREXONE, making it a notable side effect.
If you experience headache while taking NALTREXONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.